1. Home
  2. TSAT vs LUNG Comparison

TSAT vs LUNG Comparison

Compare TSAT & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Telesat Corporation

TSAT

Telesat Corporation

HOLD

Current Price

$27.41

Market Cap

368.8M

Sector

Industrials

ML Signal

HOLD

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$2.56

Market Cap

63.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TSAT
LUNG
Founded
1969
1995
Country
Canada
United States
Employees
N/A
N/A
Industry
Metal Fabrications
Industrial Specialties
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
368.8M
63.6M
IPO Year
1996
2020

Fundamental Metrics

Financial Performance
Metric
TSAT
LUNG
Price
$27.41
$2.56
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$6.81
AVG Volume (30 Days)
114.8K
1.0M
Earning Date
11-04-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$324,440,552.00
$91,664,000.00
Revenue This Year
N/A
$9.21
Revenue Next Year
N/A
$5.03
P/E Ratio
N/A
N/A
Revenue Growth
N/A
15.59
52 Week Low
$14.31
$1.31
52 Week High
$36.85
$9.37

Technical Indicators

Market Signals
Indicator
TSAT
LUNG
Relative Strength Index (RSI) 47.00 69.54
Support Level $26.83 $2.43
Resistance Level $36.77 $2.66
Average True Range (ATR) 2.37 0.20
MACD -0.08 0.06
Stochastic Oscillator 22.44 90.37

Price Performance

Historical Comparison
TSAT
LUNG

About TSAT Telesat Corporation

Telesat Corp is a satellite operator, that provides its customers with mission-critical communications services. It operates in a single operating segment, in which it provides satellite-based services to its broadcast, enterprise, and consulting customers around the world. Geographically, it derives a majority of its revenue from Canada. It derives revenue from Broadcast, Enterprise, Consulting, and others.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.

Share on Social Networks: